Hospital Acquired Infections
Desktop and Mobile
Antimicrobial-Resistance (AMR) is one of the greatest threats to human health and security, according to the World Health Organization (WHO). Superbug Infections kill more than 700,000 people annually. Vaccines are NOT A POSSIBILITY. By 2050, Superbugs are forecasted to claim 10 million lives a year and cost a cumulative $100 trillion according to a review commissioned on Antimicrobial Resistance (AMR).
Andira’s novel therapeutic strategy to address Superbug Infections involves synergistic combination of select cannabinoids with marketed antibiotics. Our Infectious Disease Program is advancing lead candidates targeting two of the Serious Threat Superbugs recognized by the U.S. Centers for Disease Control and Prevention (C.D.C.):
- Methicillin-Resistant Staphylococcus aureus (MRSA)
- Vancomycin-Resistant Enterococcus (VRE)
Tablet
Antimicrobial-Resistance (AMR) is one of the greatest threats to human health and security, according to the World Health Organization (WHO). Superbug Infections kill more than 700,000 people annually. Vaccines are NOT A POSSIBILITY. By 2050, Superbugs are forecasted to claim 10 million lives a year and cost a cumulative $100 trillion according to a review commissioned on Antimicrobial Resistance (AMR).
Andira’s novel therapeutic strategy to address Superbug Infections involves synergistic combination of select cannabinoids with marketed antibiotics. Our Infectious Disease Program is advancing lead candidates targeting two of the Serious Threat Superbugs recognized by the U.S. Centers for Disease Control and Prevention (C.D.C.):
- Methicillin-Resistant Staphylococcus aureus (MRSA)
- Vancomycin-Resistant Enterococcus (VRE)
VRE Facts:
Standard-of-Care antibiotics are failing due to antimicrobial resistance (AMR).
VRE causes a significant proportion of serious hospital-acquired infections and is associated with a high mortality rate (20-40%).
VRE costs the US $539 million annually according to the U.S. Centers for Disease Control and Prevention.
In response to this serious threat to public health,
Andira Pharmaceuticals is dedicated to developing
the following solutions:
Andira’s Lead Candidate AD02P3
Our lead candidate in pre-clinical development is an injectable therapy for hospital-based treatment of antimicrobial resistant (AMR) infections, including VRE and MRSA.
- Injectable candidate AD02P3 has a synergistic effect with a standard-of-care antibiotic already utilized in hospitals – greatly amplifying the antibacterial efficacy and reversing antimicrobial resistance (AMR).
- >500 fold improved activity versus standard-of-care antibiotic alone against multi-drug resistant Enterococcus bacteria.
- $10.6 Billion USD hospital-acquired infection (HAI) global market.
Cannabinoid-enhanced antibiotics represent a viable solution to address Hospital-Acquired Infection (HAI) and Antimicrobial Resistance (AMR)
MRSA Facts:
1-5% of Americans are colonized with MRSA bacteria.
MRSA infection is associated with a 36% mortality rate and cost the U.S. $1.7 Billion to treat in 2017.
Community-acquired MRSA causes 74% of purulent skin & soft tissue infections encountered in U.S. medical clinics. They have a 35% treatment failure rate and a 78% rate of recurrence.
Addressing MRSA with Lead Candidate AD02P3
Many MRSA infections have become resistant to last-resort antibiotics, including vancomycin (VRSA), making the need for new treatments urgent. Andira’s injectable candidate AD02P3 provides efficacy against MRSA and other multi-drug resistant bacteria through synergistic enhancement of a standard-of-care antibiotic already utilized in hospitals. Ongoing pre-clinical studies demonstrate greatly enhanced antibacterial efficacy, presenting a viable solution to this dangerous infection.
